Identification of FDA-Approved Drugs with Activity against Stationary Phase Bartonella henselae
Open Access
- 29 April 2019
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 8 (2) , 50
Abstract
Bartonella henselae can cause various infections in humans, ranging from benign and self-limiting diseases to severe and life-threatening diseases as well as persistent infections that are difficult to treat. To develop more effective treatments for persistent Bartonella infections, in this study, we performed a high-throughput screen of an FDA-approved drug library against stationary phase B. henselae using the SYBR Green I/propidium iodide (PI) viability assay. We identified 110 drug candidates that had better activity against stationary phase B. henselae than ciprofloxacin, and among the top 52 drug candidates tested, 41 drugs were confirmed by microscopy to have higher activity than the current frontline antibiotic erythromycin. The identified top drug candidates include pyrvinium pamoate, daptomycin, methylene blue, azole drugs (clotrimazole, miconazole, sulconazole, econazole, oxiconazole, butoconazole, bifonazole), aminoglycosides (gentamicin and streptomycin, amikacin, kanamycin), amifostine (Ethyol), antiviral Lopinavir/ritonavir, colistin, nitroxoline, nitrofurantoin, verteporfin, pentamidine, berberine, aprepitant, olsalazine, clinafloxacin, and clofoctol. Pyrvinium pamoate, daptomycin, methylene blue, clotrimazole, and gentamicin and streptomycin at their respective maximum drug concentration in serum (Cmax) had the capacity to completely eradicate stationary phase B. henselae after 3-day drug exposure in subculture studies. While the currently used drugs for treating bartonellosis, including rifampin, erythromycin, azithromycin, doxycycline, and ciprofloxacin, had very low minimal inhibitory concentration (MIC) against growing B. henselae, they had relatively poor activity against stationary phase B. henselae, except aminoglycosides. The identified FDA-approved agents with activity against stationary phase B. henselae should facilitate development of more effective treatments for persistent Bartonella infections.Keywords
This publication has 53 references indexed in Scilit:
- Persisters, persistent infections and the Yin–Yang modelEmerging Microbes & Infections, 2014
- Persistence ofBartonellaspp. stealth pathogens: from subclinical infections to vasoproliferative tumor formationFEMS Microbiology Reviews, 2012
- BartonellaInfection in Immunocompromised Hosts: Immunology of Vascular Infection and VasoproliferationJournal of Immunology Research, 2011
- Combining Culture Techniques for Bartonella: the Best of Both WorldsJournal of Clinical Microbiology, 2011
- Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patientsCancer Chemotherapy and Pharmacology, 2010
- Analysis of a Novel Insect Cell Culture Medium-Based Growth Medium for Bartonella SpeciesApplied and Environmental Microbiology, 2008
- Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis PatientsAntimicrobial Agents and Chemotherapy, 2007
- In vitro susceptibility of Bartonella species to 17 antimicrobial compounds: comparison of Etest and agar dilutionJournal of Antimicrobial Chemotherapy, 2006
- Pharmacokinetics of Clinafloxacin after Single and Multiple DosesAntimicrobial Agents and Chemotherapy, 2001
- Bartonella Infection in Animals: Carriership, Reservoir Potential, Pathogenicity, and Zoonotic Potential for Human InfectionClinical Microbiology Reviews, 2000